EUVIMEDEUVIMED entdecken
Crossref

L26/P-395 Is Seminal Quality Already Altered at Cancer Diagnosis? A Tumor-Type Comparison

M. Ruggeri, E. Carnesi, S. Castellano, L. Arruzzolo, G. Montanaro, P.E. Levi-Setti, E. Albani

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Ruggeri und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Is seminal quality already compromised at cancer diagnosis, and does the degree of alteration differ according to tumor type before any oncological treatment? Summary answer Seminal quality appears to be already impaired at cancer diagnosis, with significant differences across tumor types, suggesting a tumor-specific impact on spermatogenesis prior to therapy. What is known already Cancer and its treatments are established causes of male infertility, prompting fertility preservation counseling before treatment initiation. While systemic chemotherapy and radiotherapy effects on spermatogenesis are well-documented, the baseline reproductive potential of newly diagnosed cancer patients remains incompletely characterized. Previous studies suggest testicular cancer patients may present with pre-existing spermatogenic dysfunction due to local tumor effects or underlying testicular pathology. However, comprehensive comparative analyses of seminal parameters across different cancer types in treatment-naïve patients are limited, particularly regarding the differential impact of localized testicular versus systemic malignancies on specific sperm quality parameters. Study design, size, duration This retrospective study evaluated semen samples from men undergoing fertility preservation at the time of cancer diagnosis at IRCCS Humanitas Research Hospital between 2010 and 2025. Samples were stratified by tumor type into testicular cancer (TC), systemic malignancies (SM), and tumors in other sites (TOS). This classification enabled a more accurate assessment of cancer-specific differences in sperm parameters and improved interpretation of patterns in semen quality across malignancy types. Participants/materials, setting, methods Male patients diagnosed with cancer and referred for sperm cryopreservation prior to any oncological treatment were included. Samples were analyzed according to WHO guidelines. Sperm parameters (volume, concentration, total sperm count, motility, and morphology) were compared among the tumor types. Kruskal-Wallis test (followed by Dunn’s test) was performed to compare groups. Multiple linear regression identified independent predictors of sperm quality, adjusting for age as a potential confounder; statistical significance was defined as P < 0.05. Main results and the role of chance We enrolled 804 patients: 283 (35.2%) in the TC group, 290 (36.1%) in the SM group, and 231 (28.7%) in the TOS group. TC patients showed a markedly reduced sperm concentration compared with the other groups (P < 0.001), suggesting a direct local effect of cancer on spermatogenesis. Ejaculate volume was significantly lower in the SM group compared with the TC group (P = 0.003). Age differed significantly among groups (P < 0.001), with TOS patients being older than TC and SM patients (median age: 36, 33, and 29 years, respectively). Moreover, age emerged as a significant independent negative predictor of several semen parameters. Regression analysis demonstrated an estimated annual decline of approximately 0.22% in sperm viability, 0.16% in motility, and 0.03% in morphology. These findings indicate an independent and adverse effect of aging on sperm quality. Conversely, age did not appear to exert a significant negative influence on ejaculate volume or sperm concentration. This suggests that the reduction in these parameters stems from the tumor itself rather than age-related changes, confirming the negative impact of cancer on spermatogenesis. Limitations, reasons for caution The cross-sectional, retrospective design precluded longitudinal evaluation and causal inference. Testicular tumor subtypes and markers were not assessed. The absence of a healthy control group and incomplete data on lifestyle, genetic factors, comorbidities, and subclinical conditions may have introduced residual confounding. Wider implications of the findings Findings support prioritizing fertility preservation counseling for TC patients due to pre-existing spermatogenesis impairment. Future research could develop predictive models of sperm cryopreservation success and post-thaw quality, integrating tumor type, age, time from diagnosis, and lifestyle factors to guide personalized reproductive counseling and management. Trial registration number No

Zitieren

APA

Ruggeri, M., Carnesi, E., Castellano, S., Arruzzolo, L., Montanaro, G., Levi-Setti, P., & Albani, E. (2026). L26/P-395 Is Seminal Quality Already Altered at Cancer Diagnosis? A Tumor-Type Comparison. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.729

Vancouver

Ruggeri M, Carnesi E, Castellano S, Arruzzolo L, Montanaro G, Levi-Setti P, et al. L26/P-395 Is Seminal Quality Already Altered at Cancer Diagnosis? A Tumor-Type Comparison. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.729

BibTeX
@article{Ruggeri2026,
  author = {Ruggeri, M. and Carnesi, E. and Castellano, S. and Arruzzolo, L. and Montanaro, G. and Levi-Setti, P.E. and Albani, E.},
  title = {L26/P-395 Is Seminal Quality Already Altered at Cancer Diagnosis? A Tumor-Type Comparison},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.729}
}
Kostenlos starten →